Last reviewed · How we verify

NCT07297238

Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

Recruiting now NA Last updated 22 December 2025
What this trial tests

NA trial testing GLP-1 Receptor Agonists in Short Bowel Syndrome (SBS) in 20 participants. Currently enrolling.

Timeline
24 January 2026
Primary endpoint
28 February 2026
31 May 2026

Quick facts

Lead sponsorJinling Hospital, China
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment20
Start date24 January 2026
Primary completion28 February 2026
Estimated completion31 May 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Jinling Hospital, China

Who can join

Adults 18 to 80, any sex, with Short Bowel Syndrome (SBS) or Intestinal Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention. The GLP-1 group, in addition to standard care, received a subcutaneous injection of a GLP-1 analog (semaglutide injection) strictly according to the drug manufacturer's instructions. The initial dose of semaglutide was 0.25 mg once weekly. Treatment was continued over a 28-days period. Primary and secondary outcomes will be collected.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of GLP-1 Receptor Agonists

Trials testing the same drug.

Other recruiting trials for Short Bowel Syndrome (SBS)

Currently open trials in the same condition.

Other Jinling Hospital, China trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07297238.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing